Marcos Milla, . is the senior vice president of research at Synthorx. Dr. Milla’s in drug discovery spans across the areas of autoimmunity and inflammation, neurosciences and pain, and immuno-oncology. He has held industry and academic appointments at GlaxoSmithKline, Perelman School of Medicine at the University of Pennsylvania, Roche Palo Alto, Janssen Research & Development, and, most recently, Adaptive Biotechnologies. He has previously directed efforts focusing on multiple intracellular and extracellular target classes, including cell surface and nuclear receptors, ion channels, kinases and proteinases. His work led to the discovery of a break-through series of small molecule modulators of cytokine-receptor interactions. He also explored novel ways of holistically reading pharmacological responses employing high content imaging and gene expression readouts. Dr. Milla graduated with a . degree from Universidad Peruana Cayetano Heredia in Lima, Peru and a . degree in cell and molecular biology from Saint Louis University. He did his postdoctoral training at MIT as a Jane Coffin Childs Fellow and at Duke University.